Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)

Inclusion Criteria: * Written informed consent prior to any study-related procedure not part of normal medical care; * Considered to be in appropriate health for study entry by the Investigator (e.g., no acute, debilitating medical problems) and appropriate candidate for completing study treatment; * Male or female \>18 years of age; * If female of childbearing potential; willing to practice reliable birth control measures during study treatment, not lactating/pregnant, has a documented negative pregnancy test result within 24 hours prior to study medication administration, and willing to practice effective means of birth control for \>28 days after study completion; * If taking concomitant medications, subject must be on a relatively stable dose for at least two weeks prior to study medication administration; * Functioning dialysis access (e.g. graft or fistula) for subjects undergoing HD and functioning dialysis access (e.g. peritoneal catheter) for subjects undergoing CAPD; * ESRD on stable HD regimen of thrice weekly sessions with high-flux membranes or stable CAPD regimen. Exclusion Criteria: * If female, pregnant or lactating; * Received an investigational drug (including experimental biologic agents) within 30 days of study entry; * Evidence of active ongoing infection; * Unable to discontinue use of HMG-CoA reductase inhibitor therapy for duration of study; * Has received any dose(s) of daptomycin within 5 days prior to receiving the first dose of study drug; * Known to be allergic or intolerant to daptomycin; * Body Mass Index (BMI) \< 18.5 or \> 40 kg/m2 \[BMI = weight (kg)/height (m2)\]; * WBC \>12, 000 cells/mm3 or \<2500 cells/ mm3; * Baseline creatinine phosphokinase (CPK) values \>3X ULN (upper limit of normal); * Alanine aminotransferase (ALT) \>5X ULN; * Aspartate aminotransferase (AST) \>5X ULN; * Known HIV-infected subjects with CD4 count ≤200 cells/mm3; * Hemoglobin \< 9 gm/dL; * Active illicit drug and/or alcohol abuse; * Myocardial infarction within last 6 months; * Hospitalized for non-vascular or peritoneal dialysis (PD) access issues within 30 days; * Subjects with a history of muscular disease (e.g., polymyositis, muscular dystrophy); * Subjects with a history of neurological disease (e.g., Guillain Barré, multiple sclerosis), except stroke \>6 months prior to study entry; * Intramuscular injection within 7 days of study drug administration; * Has a moribund clinical condition (i.e., high likelihood of death during the next 3 days); * Is considered unlikely to comply with study procedures or to return for scheduled post-treatment evaluations; * Neutropenic subjects with absolute neutrophil count ≤500 cells/mm3 History of rhabdomyolysis.